home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

453.36 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

69 70 Next >

3 Absurdly Cheap Stocks to Buy for the Long Haul ↗

September 12, 2025

They trade at some incredibly low earnings multiples.

Via The Motley Fool

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years ↗

September 11, 2025

Via Benzinga

Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

September 11, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Fundamentals and Technical Breakout Potential ↗

September 11, 2025

Vertex Pharmaceuticals (VRTX) is a top growth stock with strong fundamentals, high profitability, and a technical setup hinting at a potential breakout for investors.

Via Chartmill

Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190% ↗

September 11, 2025

These companies are reaching key milestones.

Via The Motley Fool

1 Safe-and-Steady Stock to Research Further and 2 We Turn Down

September 11, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Why This Biotech Company Could Be a Growth Stock Powerhouse ↗

September 04, 2025

Recent developments aren't as devastating to the company's prospects as some might think.

Via The Motley Fool

Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst Reviews ↗

September 03, 2025

Via Benzinga

Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Top GARP Stock with Strong Growth and Reasonable Valuation ↗

September 03, 2025

Vertex Pharmaceuticals (VRTX) exemplifies the GARP strategy with strong growth, a reasonable valuation, high profitability, and a robust debt-free balance sheet.

Via Chartmill

Tuesday's session: top gainers and losers in the S&P500 index ↗

September 02, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.

Via Chartmill

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years ↗

September 02, 2025

Via Benzinga

3 No-Brainer Stocks to Buy Right Now ↗

August 31, 2025

Investing in these pharmaceutical stocks is an easy decision.

Via The Motley Fool

Topics World Trade

My 2 Favorite Stocks to Buy Right Now ↗

August 31, 2025

Looking for good investing ideas? These two stocks could be huge winners for long-term investors.

Via The Motley Fool

Topics Artificial Intelligence

Navigating the Currents: Top Sectors Primed for Growth in Q3 2025

August 27, 2025

The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty,...

Via MarketMinute

Topics Artificial Intelligence Economy Retirement

What's Driving the Market Sentiment Around Vertex Pharmaceuticals? ↗

August 27, 2025

Via Benzinga

Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Prime Candidate for Value Investors ↗

August 26, 2025

Vertex Pharmaceuticals (VRTX) is a top value stock with strong financials, high profitability, and impressive growth, trading below its biotech peers.

Via Chartmill

This Magnificent S&P 500 Dividend Stock Is Down 18% -- Time to Buy? ↗

August 24, 2025

It's been an unusually bad year for this drugmaker, but it's essential to look beyond that.

Via The Motley Fool

Topics Law Enforcement Stocks

2 Beaten-Down Stocks With Incredible Upside Potential ↗

August 22, 2025

These stocks should be able to rebound strongly.

Via The Motley Fool

Vertex to Participate in Upcoming September Investor Conferences

August 20, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

What's Wrong With Vertex Pharmaceuticals Stock? ↗

August 20, 2025

Shares of the pharma company are down 17% in the past 12 months.

Via The Motley Fool

2 Nasdaq 100 Stocks to Consider Right Now and 1 Facing Challenges

August 19, 2025

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing...

Via StockStory

Trump 2.0 At 200 Days: Palantir Surges, Tesla Slumps ↗

August 18, 2025

Palantir leads all stocks in the S&P 500 with a stunning 160% gain in Trump's first 200 days.

Via Benzinga

Topics Government Stocks

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns ↗

August 17, 2025

This biotech's innovative approach could pay rich dividends down the road.

Via The Motley Fool

3 Fantastic Growth Stocks to Buy in August ↗

August 17, 2025

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

Via The Motley Fool

Is This Beaten-Down Stock a Buy on the Dip? ↗

August 15, 2025

It's the second time this year the stock has slumped significantly in one day, and it might represent another attractive entry point.

Via The Motley Fool

2 Growth Stocks That Are No-Brainer Buys Right Now ↗

August 15, 2025

These stocks have outperformed broader equities over the past decade and still have room to run.

Via The Motley Fool

VRTX Q2 2025 Deep Dive: New Product Launches and Pipeline Update in a Volatile Market

August 12, 2025

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 12.1% year on year to $2.96 billion. The company expects the...

Via StockStory

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today ↗

August 11, 2025

Via Benzinga

Vertex Pharmaceuticals's Options Frenzy: What You Need to Know ↗

August 11, 2025

Via Benzinga

Exploring the top movers within the S&P500 index during today's session. ↗

August 11, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com